M&T Bank Corp Metacrine, Inc. Transaction History

M&T Bank Corp

  • $28.6 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 28, 2021
SELL
$2.61 - $3.84 $34,647 - $50,976
-13,275 Closed
0 $0
Q1 2021

May 06, 2021
BUY
$6.2 - $11.0 $9,746 - $17,292
1,572 Added 13.43%
13,275 $82,000
Q3 2020

Nov 06, 2020
BUY
$9.38 - $11.76 $109,774 - $137,627
11,703 New
11,703 $119,000

Others Institutions Holding MTCR

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Metacrine, Inc.

MTCR Quotes by TradingView
  • Ticker MTCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,569,500
  • Description
  • Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More about MTCR
Track This Portfolio

Track M&T Bank Corp Portfolio

Follow M&T Bank Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email